NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MANKIND · data 2026-10-30
Mankind Pharma Ltd.
In plain words
Price: 5.6% below its 52-week high of ₹2,642.
Delivery: 52.6% of traded shares were kept for delivery over the last 10 sessions, against 55.9% over the last 60.
Latest results: a net profit of ₹711 cr for the quarter ended Sept 2026 (+39.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹15,379 cr |
| Net profit (last 12 months) | ₹2,243 cr |
| Sales growth, 3 years (yearly) | 17.8% |
| Profit growth, 3 years (yearly) | 14.3% |
Latest results in brief (Q2 FY27)
MANKIND Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹4,337.86 crore, up 17.3% YoY and up 7.6% QoQ.
Net profit was ₹711.48 crore, up 39.1% YoY and up 23.9% QoQ.
Operating margin was 27% (24.9% a year ago).
EPS was ₹17.23, up 39.1% YoY and up 25.2% QoQ.
MANKIND के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹4,337.86 करोड़; पिछले साल की तुलना में 17.3% की बढ़त, पिछली तिमाही की तुलना में 7.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹711.48 करोड़; पिछले साल की तुलना में 39.1% की बढ़त, पिछली तिमाही की तुलना में 23.9% की बढ़त।
ऑपरेटिंग मार्जिन: 27% (एक साल पहले 24.9%)।
EPS: ₹17.23; पिछले साल की तुलना में 39.1% की बढ़त, पिछली तिमाही की तुलना में 25.2% की बढ़त।
MANKINDના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹4,337.86 કરોડ; ગયા વર્ષની સરખામણીએ 17.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 7.6% વધારો.
ચોખ્ખો નફો: ₹711.48 કરોડ; ગયા વર્ષની સરખામણીએ 39.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 23.9% વધારો.
ઓપરેટિંગ માર્જિન: 27% (એક વર્ષ પહેલાં 24.9%).
EPS: ₹17.23; ગયા વર્ષની સરખામણીએ 39.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 25.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
26/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 49.1% over the last 20 sessions vs 54.5% in the 40 before (0.9x); shares delivered per day 1.49x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 36 schemes hold it, about ₹5,781 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 53/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 26 Oct 26Results Q2 FY27 results: profit +39.1% YoY +13.1% next session
- 30 Jul 26Results Q1 FY27 results: profit +31.0% YoY -4.7% next session
- 19 May 26Results Q4 FY26 results: net profit ₹554.4 cr +3.5% next session
- 3 Feb 26Results Q3 FY26 results: profit +7.5% YoY +1.2% next session
- 6 Nov 25Results Q2 FY26 results: profit −21.7% YoY -4.5% next session
- 8 Aug 25Dividend Dividend ₹1 (ex-date) -4.0% next session
- 31 Jul 25Results Q1 FY26 results: profit −18.3% YoY -0.4% next session
- 21 May 25Results Results board meeting -4.3% next session
- 24 Jan 25Results Q3 FY25 results: profit −16.2% YoY -6.9% next session
- 5 Nov 24Results Q2 FY25 results: profit +30.4% YoY +0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹4,338 cr | ₹711 cr | +39.1% | 27.0% | 17.23 |
| Jun 2026 | ₹4,031 cr | ₹574 cr | +31.0% | 26.2% | 13.76 |
| Mar 2026 | ₹3,443 cr | ₹554 cr | — | 27.0% | 13.44 |
| Dec 2025 | ₹3,567 cr | ₹409 cr | +7.5% | 25.8% | 9.9 |
Common questions
What was Mankind Pharma Ltd.'s latest quarterly profit?
Mankind Pharma Ltd. reported a net profit of ₹711 cr for the quarter ended Sept 2026 (+39.1% on the same quarter a year earlier), on revenue of ₹4,338 cr.
Is Mankind Pharma Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.39.
What is Mankind Pharma Ltd.'s P/E ratio?
About 46, based on the last 12 months' earnings and a price of ₹2,492.8 (data 2026-10-30).
What is the 52-week high and low of Mankind Pharma Ltd.?
The 52-week high is ₹2,642 and the 52-week low is ₹1,909.7.
Mutual funds holding Mankind Pharma Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 36 schemes holding about ₹5,781 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large Cap Fund | SBI Mutual Fund | 1.95% | ₹1,021 cr |
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 1.95% | ₹978 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 1.04% | ₹534 cr |
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.85% | ₹518 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 4.38% | ₹402 cr |
| ADITYA BIRLA SUN LIFE LARGE CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.35% | ₹377 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 1.83% | ₹358 cr |
| SBI Contra Fund | SBI Mutual Fund | 0.74% | ₹334 cr |
| Nippon India ELSS Tax Saver Fund | Nippon India Mutual Fund | 1.59% | ₹224 cr |
| Nippon India Flexi Cap Fund | Nippon India Mutual Fund | 1.87% | ₹172 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.71% | ₹100 cr |
| ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND | Aditya Birla Sun Life Mutual Fund | 0.73% | ₹99 cr |
| ADITYA BIRLA SUN LIFE LARGE & MID CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.54% | ₹86 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.24% | ₹78 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.15% | ₹67 cr |
Similar companies
Laurus Labs Ltd. (LAURUSLABS) · Zydus Lifesciences Limited (ZYDUSLIFE) · Dr. Reddy's Laboratories Ltd. (DRREDDY) · Glenmark Pharmaceuticals Limited (GLENMARK) · Alkem Laboratories Ltd. (ALKEM)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MANKIND in NSE Scanner →